References
Suehara Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, Itoh T, Kaji D, Yamamoto G, Abe Y, Narita K, Takeuchi M, Matsue K, Sato T, Noguchi M, Baba N, Sakamoto T, Kusakabe M, Kurita N, Kato T, Yokoyama Y, Nishikii H, Obara N, Hasegawa Y, Chiba S (2018) Liquid biopsy for the identification of intravascular large B-cell lymphoma. Haematologica 103(6):e241–e244. https://doi.org/10.3324/haematol.2017.178830
Ponzoni M, Campo E, Nakamura S (2018) Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood 132(15):1561–1567. https://doi.org/10.1182/blood-2017-04-737445
Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Kikuchi Y, Ouchi T, Takeuchi K, Matsue K (2018) Clinical value of abnormal findings on brain magnetic resonance imaging in patients with intravascular large B-cell lymphoma. Ann Hematol 97(12):2345–2352. https://doi.org/10.1007/s00277-018-3481-8
Wu FT, Lu L, Xu W, Li JY (2019) Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma. Ann Hematol 98(2):255–269. https://doi.org/10.1007/s00277-018-3529-9
Melani C, Wilson WH, Roschewski M (2019) Liquid biopsy in non-Hodgkin’s lymphoma. Hematol Oncol 37 Suppl 1:70–74. https://doi.org/10.1002/hon.2587
Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, Jiwa NM, de Boer M, Leguit RJ, de Weger RA, Huibers MMH (2018) The use of droplet digital PCR in liquid biopsies: a highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol Oncol 36(2):429–435. https://doi.org/10.1002/hon.2489
Ferreri AJM, Calimeri T, Lopedote P, Francaviglia I, Daverio R, Iacona C, Belloni C, Steffanoni S, Gulino A, Anghileri E, Diffidenti A, Finardi A, Gagliardi F, Anzalone N, Nonis A, Furlan R, De Lorenzo D, Terreni MR, Martinelli V, Sassone M, Foppoli M, Angelillo P, Guggiari E, Falini A, Mortini P, Filippi M, Tarantino V, Eoli M, Ciceri F, Doglioni C, Tripodo C, Locatelli M, Cangi MG, Ponzoni M (2021) MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. Br J Haematol 193(3):497–505. https://doi.org/10.1111/bjh.17357
Rimelen V, Ahle G, Pencreach E, Zinniger N, Debliquis A, Zalmaï L, Harzallah I, Hurstel R, Alamome I, Lamy F, Voirin J, Drénou B (2019) Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun 7(1):13. https://doi.org/10.1186/s40478-019-0692-8
Fontanilles M, Marguet F, Bohers É, Viailly PJ, Dubois S, Bertrand P, Camus V, Mareschal S, Ruminy P, Maingonnat C, Lepretre S, Veresezan EL, Derrey S, Tilly H, Picquenot JM, Laquerrière A, Jardin F (2017) Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget 8(29):48157–48168. https://doi.org/10.18632/oncotarget.18325
Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, Kataoka K, Yuge M, Takagi Y, Kusumoto S, Masaki Y, Ito T, Inagaki Y, Okamoto A, Kuwatsuka Y, Nakatochi M, Shimada S, Miyoshi H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shiozawa Y, Nannya Y, Okabe A, Kohno K, Atsuta Y, Ohshima K, Nakamura S, Ogawa S, Tomita A, Kiyoi H (2021) Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma. Blood 137(11):1491–1502. https://doi.org/10.1182/blood.2020007245
Acknowledgements
We thank the patients and clinical staff at Wakayama Medical University Hospital for their participation in this study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the ethics committee of Wakayama Medical University (No. 2919). All procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the relevant institutional and/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Consent for publication
Informed consent was obtained from the patient.
Conflict of interest
Akihiro Tomita received lecture fee from Chugai Pharmaceutical, Takeda Pharmaceutical, and research fund from Perseus Proteomics Inc, Novartis Phama K.K., Pfizer Japan Inc, Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, Taiho Pharmaceutical. The other authors declare that they have no conflicts of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
277_2021_4572_MOESM1_ESM.pdf
Supplementary file1 Supplementary Fig. 1 Magnetic resonance imaging (MRI) findings obtained with diffusion-weighted imaging (left; DWI) and T1-weighted imaging (right; T1WI). Acute ischemic stroke (arrow) and minor bleeding (arrowhead) were also seen. Supplementary Fig. 2 Microscopic features of the frontal lobe brain biopsy specimen. The number of atypical cells in the blood vessels were too small to allow a definitive diagnosis to be made. Hematoxylin-eosin staining, x40. Supplementary Fig. 3 MRI findings obtained before and after the first course of chemotherapy. The patient’s MRI findings improved after one cycle of combination chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone). FLAIR, T2-weighted fluid-attenuated inversion recovery; CE-MRI, contrast-enhanced MRI; CTx, chemotherapy. (PDF 24410 KB)
Rights and permissions
About this article
Cite this article
Hosoi, H., Tanigawa, I., Kosako, H. et al. Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone. Ann Hematol 101, 709–711 (2022). https://doi.org/10.1007/s00277-021-04572-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04572-2